Cohort 8.0 founders Garland Surgical have been awarded up to €1.4 million in grant funding by Malta Enterprise.
We are incredibly excited to bring you some fantastic news from Cohort 8.0 founders Garland Surgical. Garland, who are developing a revolutionary longer-lasting hip replacement - the MaltaHip have been approved for up to €1.4 million in grant funding by Malta Enterprise - the economic development agency for Malta.
Aimed at helping Garland push the MaltaHip towards regulatory approval and market launch, Malta Enterprise's grant offering also includes laboratory space at the Malta Life Sciences Park, key for further research and development.
We are tremendously proud to see the confidence and support that has been generated in the MaltaHip project and look forward to seeing the continued journey towards fully-fledged public use.
To read the full LinkedIn post from Garland Surgical, use the link here.
09 Oct 2025 | Cohort Successes
BetaDen Incubate Intake 5.0 founders Filmshake have officially launched their platform, as the 2025...


07 Oct 2025 | Cohort Successes
We’re proud to share that four of our alumni have been named as finalists in the 2025 NW Business...


01 Oct 2025 | Cohort Successes
BetaDen Accelerate Cohort 2.0 alumni FARx have secured £14,000 of grant funding through Innovation...

